Medical/Pharmaceuticals

Atonarp Announces $50M Series D Financing to Scale its Molecular Sensing and Digital Diagnostics Testing Platforms

Michael Marks, Founding Partner for WRVI Capital, Joins the Atonarp Board and Former Berkeley Lights CFO Shaun Holt Joins as Atonarp's Chief Operating Officer TOKYO, May 18, 2021 /PRNewswire/ -- Atonarp, a leading manufacturer of molecular sensing and diagnostics products for the healthcare, phar...

2021-05-18 18:00 3337

Nanoform's final clinical results confirm value proposition to the pharma industry

HELSINKI, Finland, May 18, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform "), an innovative nanoparticle medicine enabling company, today announced the completion and final results of its clinical study. The primary, secondary and optional exploratory objectives of the study were all met. Th...

2021-05-18 13:48 1469

U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, May 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) today jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in...

2021-05-18 12:14 13166

Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern

* The publication is available as a pre-print on bioRxiv * Preclinical data demonstrates that a modified B.1.351 S-Trimer vaccine candidate induces broad neutralization against both the original SARS-CoV-2 strain and variants of concern (VoC) including the South African variant * A single bo...

2021-05-18 11:50 3165

Mycenax becomes Taiwan's first CDMO company to complete the CHO-S and CHOZN GS Cell Line Development with the Beacon(R) Optofluidic System

TAIPEI, May 18, 2021 /PRNewswire/ -- Mycenax (TWSE: 4726) becomes one of the first CDMO companies inAsia to adapt the Beacon Optofluidic system to cell line development services. Mycenax adopted Beacon® Optofluidic System, a high throughput selection system for single-cell cloning and quantifica...

2021-05-18 10:32 14352

Hummingbird Bioscience Raises US$125 Million in Series C Financing

* Investment round led by Novo Holdings, joined by a syndicate of international biotech investors * Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision therapeutics * Kenneth Harrison from Novo Ventures ...

2021-05-18 09:35 3057

Farrer Park Hospital Elevates Cancer Care with PIPAC Treatment for Late to End-stage Cancer Patients

SINGAPORE, May 18, 2021 /PRNewswire/ -- Farrer Park Hospital has introduced the pressurized intraperitoneal aerosolized chemotherapy (PIPAC) treatment for patients with peritoneal cancer, off...

2021-05-18 08:15 2267

AI-for-COVID19: Predictive Diagnostics Platform Available to Global Scientific Community

The "AIforCOVID Imaging Archive" platform enables the sharing of radiographic images from COVID-19 patients and development of leading-edge Artificial Intelligence-based methods for predicting clinical developments of the disease caused by SARS-CoV-2. The platform has been promoted and implement...

2021-05-18 04:44 1696

ISMRM Awards Gold Medals At Annual Meeting And Announces New President

CONCORD, Calif., May 17, 2021 /PRNewswire/ -- The International Society for Magnetic Resonance in Medicine (ISMRM) is holding its Annual Meeting this week and will recognize several achievements with prestigious awards. The Gold Medal award is the organization's highest honor and is awarded to r...

2021-05-17 23:00 2682

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

PROVIDENCE, R.I., May 17, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation" in NPJ Vaccines. This research identifies peptide epitopes associated with T...

2021-05-17 20:54 2460

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in he...

2021-05-17 20:35 4346

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

Dr. Dansey, Seagen's Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands the Board's diverse industry, clinical development, research and commercialization expertise PLYMOUTH MEETING, Pa., May 17, 20...

2021-05-17 20:00 4594

Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

SHANGHAI, May 17, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inGreater China and other parts of Asia, announced today that the C...

2021-05-17 16:51 4123

Cynosure Announces Grand Opening of State-of-the-Art Experience Centre in London

Industry-leading Centre will provide new collaborative and experiential environment for research, training, and treatments LONDON, May 17, 2021 /PRNewswire/ -- Cynosure announced today the grand opening of its new Cynosure Experience Centre inLondon. Complete with new research and training facil...

2021-05-17 16:00 2341

Cynosure Announces Grand Opening of State-of-the-Art Experience Centre in London

Industry-leading Centre will provide new collaborative and experiential environment for research, training, and treatments LONDON, May 17, 2021 /PRNewswire/ -- Cynosure announced today the grand opening of its new Cynosure Experience Centre inLondon. Complete with new research and training facil...

2021-05-17 16:00 1910

Nippon Express (China) Becomes First Japanese Company to Acquire GDP Certification in China

TOKYO, May 17, 2021 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NE China"), a local subsidiary of Nippon Express Co., Ltd., has obtained Good Distribution Practice (GDP) certification, effectiveMonday, March 29, 2021, for its Shanghai Pudong Airport CFS, making it the first Jap...

2021-05-17 15:00 4279

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2021-05-17 09:00 4965

ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypertension

PALO ALTO, Calif., May 17, 2021 /PRNewswire/ -- ReCor Medical, Inc. ("ReCor"), a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., today presented the primary endpoint data from the randomized sham-controlled RADIANCE-HTN TRIO ("TRIO") study.  In subjects with resistant hypertension, t...

2021-05-17 08:24 1816

Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onc...

2021-05-17 08:00 3396

China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

HAIKOU, China, May 14, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2021. Revenue increased by 33.7% to $2.4 million for the thr...

2021-05-15 04:30 9947
1 ... 606607608609610611612 ... 646

Week's Top Stories